427
Views
11
CrossRef citations to date
0
Altmetric
Review

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes

, &
Pages 1133-1152 | Received 09 Jan 2016, Accepted 21 Jul 2016, Published online: 05 Aug 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

K. Pafili & N. Papanas. (2019) Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Review of Clinical Pharmacology 12:8, pages 693-695.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2018) Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?. Expert Opinion on Pharmacotherapy 19:3, pages 185-187.
Read now
Cheng Xiu, Zhou Hua, Bao sheng Xiao, Wen Jian Tang, Hai Pin Zhou & Xin Hua Liu. (2017) Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016). Expert Opinion on Therapeutic Patents 27:9, pages 1031-1045.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2017) Dapagliflozin for the treatment of type 1 diabetes mellitus. Expert Opinion on Investigational Drugs 26:7, pages 873-881.
Read now

Articles from other publishers (7)

Jianlong Zhai, Zhongli Wang, Tingting Zhang, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Xinyu Wang & Yifang Guo. (2023) Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats. Journal of International Medical Research 51:10.
Crossref
Zhenwang Zhang, Ping Ni, Mingqiu Tang, Yi Song, Chao Liu & Baoqing Zhao. (2023) Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis. Molecular Medicine Reports 28:5.
Crossref
Krit Jaikumkao, Sasivimon Promsan, Laongdao Thongnak, Myat T. Swe, Monruedee Tapanya, Khin T. Htun, Suchart Kothan, Nuttawadee Intachai & Anusorn Lungkaphin. (2021) Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats. Journal of Cellular Physiology 236:9, pages 6424-6440.
Crossref
Kalliopi Pafili & Michael Roden. (2021) Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism 50, pages 101122.
Crossref
Fengjuan Huang, Yanyan Zhao, Qingzhu Wang, Jan-Luuk Hillebrands, Jacob van den Born, Linlin Ji, Tingting An & Guijun Qin. (2019) Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. Frontiers in Endocrinology 10.
Crossref
Prashanth R. J. Vas, Periklis Panagopoulos & Nikolaos Papanas. (2018) Diabetic Foot Fungal Osteomyelitis: No Longer Unknown and Hidden?. The International Journal of Lower Extremity Wounds 17:3, pages 142-143.
Crossref
Zheng Li, Xue Xu, Liming Deng, Ruoxian Liao, Ruiying Liang, Bo Zhang & Luyong Zhang. (2018) Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Bioorganic & Medicinal Chemistry 26:14, pages 3947-3952.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.